<?xml version="1.0" encoding="UTF-8"?>
<p>There are several plant-based natural compounds which are either under investigation, in preclinical trials or in clinical trials. Two such plant-based antiviral compounds under clinical trials are (+)-Calanolide A and SP-303. Calanolide A is isolated from the 
 <italic>Calophyllum langigerum,</italic> and is mostly found in Malaysia. It is a C22 coumarin mostly used for the treatment of HIV infection [
 <xref rid="B285-plants-09-01244" ref-type="bibr">285</xref>,
 <xref rid="B286-plants-09-01244" ref-type="bibr">286</xref>,
 <xref rid="B287-plants-09-01244" ref-type="bibr">287</xref>]. This natural product has completed the phase 1 clinical trial (NCT00002243). On the other hand, SP-303 is isolated from the latex of a Latin American plant 
 <italic>Croton lechleri.</italic> However, this natural compound is the mixture of oligomeric proanthocyanidins with a molecular weight of 2100 daltons [
 <xref rid="B285-plants-09-01244" ref-type="bibr">285</xref>,
 <xref rid="B288-plants-09-01244" ref-type="bibr">288</xref>]. SP-303 is used for the treatment of HSV and HIV infection. It is currently under clinical trial (NCT00002408). Furthermore, seven known FDA-approved antiviral drugs (famciclovir, ganciclovir, sorivudine, zidovudine, didanosine, zalcitabine and stavudine) are originally modeled on a natural product parent [
 <xref rid="B285-plants-09-01244" ref-type="bibr">285</xref>].
</p>
